STOK logo

STOKStoke Therapeutics Inc

$29.50
$0.97
(3.18%)
Today
Updated: 10:33 AM EDT
Reported EarningsMay 7
Mkt Cap$1.9B
Vol37,630.00
News
all
press releases
Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates
Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates...
Yahoo! Finance: News
News Placeholder
More News
News Placeholder
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet...
Business Wire
News Placeholder
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
STOK rides high as zorevunersen advances in late-stage Dravet syndrome studies and heads toward FDA filing plans.
Zacks
News Placeholder
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire
News Placeholder
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +0.94% and +18.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire
News Placeholder
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +25.42% and -60.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Thursday
Stoke Therapeutics (NASDAQ:STOK) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...
MarketBeat
News Placeholder
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire
News Placeholder
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of "Moderate Buy" by Brokerages
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twelve brokerages that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, nine have issued a buy reco...
MarketBeat
<
1
2
...
>